Behrens GM - Search Results

1

Behrens GM, Reiss P. Behrens GM, et al. Curr Opin Infect Dis. 2010 Feb;23(1):9-14. doi: 10.1097/QCO.0b013e328334fe84. Curr Opin Infect Dis. 2010. PMID: 19996748 Review.

2

Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Behrens GM, Stoll M, Schmidt RE. Behrens GM, et al. Drug Saf. 2000 Jul;23(1):57-76. doi: 10.2165/00002018-200023010-00004. Drug Saf. 2000. PMID: 10915032 Review.

3

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.

van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P; Atlantic Study Team. van der Valk M, et al. AIDS. 2001 Dec 7;15(18):2407-14. doi: 10.1097/00002030-200112070-00008. AIDS. 2001. PMID: 11740191 Clinical Trial.

4

Treatment options for lipodystrophy in HIV-positive patients.

Behrens GM. Behrens GM. Expert Opin Pharmacother. 2008 Jan;9(1):39-52. doi: 10.1517/14656566.9.1.39. Expert Opin Pharmacother. 2008. PMID: 18076337 Review.

5

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, Martinez E, Nair D, Powderly WG, Reiss P, Sutinen J, Vigano A; EACS Executive Committee. Lundgren JD, et al. HIV Med. 2008 Feb;9(2):72-81. doi: 10.1111/j.1468-1293.2007.00534.x. HIV Med. 2008. PMID: 18257770 Free article.

6

Interleukin-2 therapy in patients with HIV infection.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.

7

Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.

Stankov MV, Behrens GM. Stankov MV, et al. Among authors: behrens gm. Curr Pharm Des. 2010 Oct;16(30):3361-71. doi: 10.2174/138161210793563473. Curr Pharm Des. 2010. PMID: 20687889 Review.

8

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G. Behrens G, et al. Antivir Ther. 2012;17(6):1011-20. doi: 10.3851/IMP2305. Epub 2012 Aug 15. Antivir Ther. 2012. PMID: 22910324 Clinical Trial.

9

Liver fibrosis in HIV: which role does HIV itself, long-term drug toxicities and metabolic changes play?

Rockstroh JK, Mohr R, Behrens G, Spengler U. Rockstroh JK, et al. Curr Opin HIV AIDS. 2014 Jul;9(4):365-70. doi: 10.1097/COH.0000000000000064. Curr Opin HIV AIDS. 2014. PMID: 24840057 Review.

10

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Nordell AD, et al. J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844. J Am Heart Assoc. 2014. PMID: 24870935 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

202 results

Search Page